Is it finally here? Reversing sensorineural hearing loss by hearing hair cell regeneration?

It sure looks like it. According to this, the company has dosed 200 people thus far with success. Their measurement for hearing improvement is improvement in speech perception.

Clearly, this tech is still several years (at least a decade?) off, but the fact that they have finally made some progress in this area is astounding.

Reversing hearing loss with regenerative therapy

MIT spinout Frequency Therapeutics’ drug candidate stimulates the growth of hair cells in the inner ear.

Most of us know someone affected by hearing loss, but we may not fully appreciate the hardships that lack of hearing can bring. Hearing loss can lead to isolation, frustration, and a debilitating ringing in the ears known as tinnitus. It is also closely correlated with dementia.

The biotechnology company Frequency Therapeutics is seeking to reverse hearing loss — not with hearing aids or implants, but with a new kind of regenerative therapy. The company uses small molecules to program progenitor cells, a descendant of stem cells in the inner ear, to create the tiny hair cells that allow us to hear.

Hair cells die off when exposed to loud noises or drugs including certain chemotherapies and antibiotics. Frequency’s drug candidate is designed to be injected into the ear to regenerate these cells within the cochlea. In clinical trials, the company has already improved people’s hearing as measured by tests of speech perception — the ability to understand speech and recognize words.

“Speech perception is the No. 1 goal for improving hearing and the No. 1 need we hear from patients,” says Frequency co-founder and Chief Scientific Officer Chris Loose PhD ’07.

In Frequency’s first clinical study, the company saw statistically significant improvements in speech perception in some participants after a single injection, with some responses lasting nearly two years.

The company has dosed more than 200 patients to date and has seen clinically meaningful improvements in speech perception in three separate clinical studies. Another study failed to show improvements in hearing compared to the placebo group, but the company attributes that result to flaws in the design of the trial.

Now Frequency is recruiting for a 124-person trial from which preliminary results should be available early next year.

There have been a number of forum posts and articles on this company over the years. Enter “Frequency Therapeutics” into the search box. That will give you some of them.

The most recent post that I know of is It discusses the same article that you mention. A bit of a fluff piece in my view.

Once upon a time, I was as excited about them as you are now. Yeah, it might still come good. Here’s to positivity.

1 Like